Zymeworks Inc. (ZYME)
Nasdaq: ZYME · Pharmaceutical Preparations · Middletown, DE · filing with the SEC since 2022
Who owns Zymeworks Inc.
As filed with the SECHolders of 5% or more
4
EcoR1 Capital, LLC holds 30.7% of Common Stock, as its SCHEDULE 13D/A filed Nov 19, 2025 says.
Directors and officers
17
report now, of 30 people on the record since 2022. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
EcoR1 Capital, LLC
SCHEDULE 13D/A · filed Nov 19, 2025 · Common Stock · 30.7% in Jun 27, 2025
Rubric Capital Management LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.00001 par value per share · 7.68% in Feb 13, 2026
Perceptive Advisors LLC
SCHEDULE 13G · filed Apr 15, 2026 · Common Stock, $0.00001 par value per share
Bvf Partners L P/il
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.00001 par value per share
Redmile Group, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 5.6% in Aug 14, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 16, 2025 · Common Stock · reported falling below 5%
Morgan Stanley
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock · reported falling below 5%, from 5.8% in May 7, 2025
What ZYME reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Zymeworks BC Inc
An entity · legal entity · owns, named in the 10-K filed Mar 2, 2026
10 subsidiaries in 5 countries, from the list filed with the 10-K filed Mar 2, 2026.
Insider tradesForm 4
11sales
0purchases
0sales on a scheduled plan
5people selling
$5.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 9, 2025 to Oct 9, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 9, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 32 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Galbraith Kenneth | Chair & CEO | 4 | $3.3M | 0 | 0 | $0 |
| Moore Paul Andrew | Chief Scientific Officer | 3 | $700,000 | 0 | 0 | $0 |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 2 | $500,000 | 0 | 0 | $0 |
| Schayowitz Adam | EVP, Head of R&D | 1 | $400,000 | 0 | 0 | $0 |
| Hollywood Mark | EVP & Chief Operating Officer | 1 | $100,000 | 0 | 0 | $0 |